Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abdullah M Khan

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Frontiers in Oncology|March 4, 2021
Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma PatientsFrancesca Cottini, Ying Huang, Nita Williams, et al.
Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society|October 10, 2022
Risk factors, complications, and outcomes of phacoemulsification cataract surgery complicated by retained lens fragments in Asian eyes: A 10-year retrospective studyHalah B Helayel, Ahmed A Alyahya, Adi M Al Owaifeer, et al.
Frontiers in Oncology|August 9, 2023
Impact of interval progression before autologous stem cell transplant in patients with multiple myelomaAlicia Bao, Qiuhong Zhao, Ruchi Kudalkar, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 29, 2022
Outcomes After Salvage Autologous Hematopoietic Cell Transplant for Patients With Relapsed/Refractory Multiple Myeloma: A Single-Institution ExperienceAbdullah M Khan, Michael Ozga, Harshil Bhatt, et al.
American Journal of Ophthalmology|July 20, 2021
Coincident PAMM and AMN and Insights Into a Common PathophysiologyClaudio Iovino, Adrian Au, Prithvi Ramtohul, et al.
Journal for Immunotherapy of Cancer|December 2, 2024
Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphomaFabian Ullrich, Paul J Bröckelmann, Amin T Turki, et al.
Cancers|June 26, 2026
Moving Mountains: Improving Access to Autologous Stem Cell Transplant for Vulnerable Patient PopulationsSrinivas Devarakonda, Qiuhong Zhao, Suzanne Keirns, et al.
Advances in Therapy|August 6, 2025
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple MyelomaCyrille Touzeau, Brea Lipe, Abdullah M Khan, et al.
Blood Reviews|September 30, 2025
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologistsAli Mushtaq, Asfand Yar Cheema, Hossam M Ali, et al.
Advances in Therapy|May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect ComparisonNoemi Puig, Joris Diels, Suzy van Sanden, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|March 4, 2021
Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma PatientsFrancesca Cottini, Ying Huang, Nita Williams, et al.
Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society|October 10, 2022
Risk factors, complications, and outcomes of phacoemulsification cataract surgery complicated by retained lens fragments in Asian eyes: A 10-year retrospective studyHalah B Helayel, Ahmed A Alyahya, Adi M Al Owaifeer, et al.
Frontiers in Oncology|August 9, 2023
Impact of interval progression before autologous stem cell transplant in patients with multiple myelomaAlicia Bao, Qiuhong Zhao, Ruchi Kudalkar, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 29, 2022
Outcomes After Salvage Autologous Hematopoietic Cell Transplant for Patients With Relapsed/Refractory Multiple Myeloma: A Single-Institution ExperienceAbdullah M Khan, Michael Ozga, Harshil Bhatt, et al.
American Journal of Ophthalmology|July 20, 2021
Coincident PAMM and AMN and Insights Into a Common PathophysiologyClaudio Iovino, Adrian Au, Prithvi Ramtohul, et al.
Journal for Immunotherapy of Cancer|December 2, 2024
Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphomaFabian Ullrich, Paul J Bröckelmann, Amin T Turki, et al.
Cancers|June 26, 2026
Moving Mountains: Improving Access to Autologous Stem Cell Transplant for Vulnerable Patient PopulationsSrinivas Devarakonda, Qiuhong Zhao, Suzanne Keirns, et al.
Advances in Therapy|August 6, 2025
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple MyelomaCyrille Touzeau, Brea Lipe, Abdullah M Khan, et al.
Blood Reviews|September 30, 2025
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologistsAli Mushtaq, Asfand Yar Cheema, Hossam M Ali, et al.
Advances in Therapy|May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect ComparisonNoemi Puig, Joris Diels, Suzy van Sanden, et al.
Pageof 4